Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Operating Expenses (2017 - 2025)

Cue Biopharma's Operating Expenses history spans 9 years, with the latest figure at $9.7 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 19.81% year-over-year to $9.7 million; the TTM value through Sep 2025 reached $45.3 million, down 18.05%, while the annual FY2024 figure was $50.8 million, 11.89% down from the prior year.
  • Operating Expenses for Q3 2025 was $9.7 million at Cue Biopharma, down from $11.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $16.1 million in Q4 2021 and bottomed at $9.7 million in Q3 2025.
  • The 5-year median for Operating Expenses is $13.5 million (2023), against an average of $13.5 million.
  • The largest annual shift saw Operating Expenses surged 42.08% in 2021 before it decreased 28.39% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $16.1 million in 2021, then decreased by 7.0% to $15.0 million in 2022, then rose by 4.24% to $15.7 million in 2023, then fell by 28.39% to $11.2 million in 2024, then dropped by 13.07% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Operating Expenses are $9.7 million (Q3 2025), $11.6 million (Q2 2025), and $12.7 million (Q1 2025).